H. Lundbeck A/S (Lundbeck) today announced the acceptance of its new drug application (NDA) for Vyepti® (eptinezumab) by the Ministry of Health, Labor and Welfare (MHLW) in Japan.
Rapala VMC Corporation, Inside Information, November 14, 2025 at 10:25 a.m. EET NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback